ライフサイエンスコーパス: aged @1 years

1 at least 2 years and data on older patients (aged >=75 years).

2 ients hospitalized with RSV (61% female, 64% aged >=75 years).

3 spiratory infection (ALRI) in young children aged <5 years.

4 olonization and invasive disease in children aged <5 years.

5 d to 10.4% (95% CI, 5.0-15.8) in individuals aged 80+ years.

6 are clinical signs and symptoms for children aged <18 years.

7 or those aged >=75 years compared with those aged <75 years.

8 etard skin aging among healthy men and women aged >45 years.

9 ovascular hospitalizations among individuals aged >65 years.

10 (total HAV antibody negative) among persons aged >=2 years.

11 ecreased by 38%, neither decreased in people aged >=5 years.

12 No association was found among adults aged <=45 years.

13 sectional study was conducted among students aged >=18 years.

14 o select the study participants from adult's aged >=18 years.

15 Eligible patients were aged >=50 years.

16 vident in strokes of CE origins and in those aged >=55 years.

17 inical trial was performed in healthy adults aged >=60 years.

18 ed HZ incidence among immunocompetent adults aged >=60 years.

19 ients aged <30 years but only 1 (2.7%) of 37 aged >=60 years.

20 ruses in the etiology of ARI in older adults aged >=65 years.

21 among Medicare Fee-for-Service beneficiaries aged >=65 years.

22 a substantial disease burden in older adults aged >=65 years.

23 ferent doses/formulations) in healthy adults aged >=65 years.

24 reatinine clearance <60 mL/min, and 35% were aged >=65 years.

25 This effect was most pronounced among those aged >=75 years.

26 aged <=63 years) and older patients (n = 514 aged >=64 years) (14 [IQR, 12-15] vs 14 [IQR, 12-16] cm

27 Among adults aged >=65 years, 17.3% reported vision impairment, of wh

28 unique patients were included: 225 children (aged <18 years), 186 adults (18-65 years), and 51 older

29 groups were held with 39 total ESKD patients aged >=50 years (19 transplant candidates, 20 transplant

30 ifferentiate carriers from non-carriers when aged 22 years (22 years before the estimated median age

31 Many patients were aged <5 years (42.6%) or >=65 years (20.7%).

32 In children aged < 5 years, 57%-72% of RTI admissions with specified

33 se mutually exclusive groups: 102 (10%) were aged <5 years; 63 (6%) were aged >=5 and were infected w

34 ng scalp but prominent in the scalp of those aged >40 years, accompanied by reduced podoplanin (PDPN)

35 A retrospective, cohort study of PWID aged >=18 years admitted to a tertiary referral center b

36 We prospectively identified adult patients (aged >=18 years) admitted to both hospitals from March 2

37 against HZ in healthy immunocompetent adults aged >=50 years after vaccination.

38 All patients aged 18 years and above who underwent noncardiac and non

39 to collect data among 230 diabetic patients aged 18 years and above.

40 ed, phase 2/3 trial (COV002), healthy adults aged 18 years and older were enrolled at two UK clinical

41 Participants aged 18 years and older were randomly assigned (1:1) to

42 e, Black (B) race, or Hispanic (H) ethnicity aged 18 years and older with diabetic macular edema who

43 een October 2017 and June 2018, 245 patients aged 18 years and older with iron-deficiency anemia (hem

44 Women aged 18 years and older with stage III/IV high-grade ser

45 patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute res

46 re living-donor kidney transplant recipients aged 18 years and older.

47 ical cohorts of patients with clear cell RCC aged 18 years and older.

48 nd outcome data were collected on all adults aged 18 years and over undergoing surgery requiring at l

49 ses both stunting and overweight in children aged 4 years and older by providing school meals with im

50 ) reported that they did not screen patients aged 40 years and above for cataract.

51 entative survey, and their household members aged 5 years and older.

52 in children younger than 5 years and adults aged 55 years and older in Fiji, 5 years after vaccine i

53 24-59 months, and 1.90 (1.53-2.31) in adults aged 55 years and older, 5 years after PCV10 introductio

54 imal; its use should be restricted to people aged 55 years and older, or to those with concerning fea

55 Berlin Aging Study II (BASE-II) participants aged 60 years and older (52.2% women, mean age 68 +/- 4

56 We used data for participants aged 60 years and older from the English Longitudinal St

57 tion and analysis; (b) included participants aged 60 years and older regardless of the study context;

58 77 US cities and for the Medicare population aged 65 years and older across 3,113 US counties, respec

59 The proportion of people aged 65 years and older increased globally from 6.1% to

60 opulation includes 5.04 million more persons aged 65 years and older than the average population in 2

61 ider range of participants, including adults aged 70 years and older.

62 m appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure low

63 n patients aged 40-49 years to 0.48 in those aged 80 years and older.

64 enteric fever hospitalization among children aged <15 years and identify risk factors for hospitaliza

65 Of women with a CA125 level >=35 U/ml, 3.4% aged <50 years and 15.2% aged >=50 years had ovarian can

66 uring October 1, 2018 through March 31, 2019 aged >= 18 years and self-identified as black or white r

67 Couples (n = 2370; men aged >=18 years and women aged 18-45 years) planning inf

68 The data were collected from individuals aged >=30 years and included 3,624 participants in the U

69 seven multidisciplinary ICUs, 302 patients, aged >=40 years and requiring >=4 hours of vasopressor s

70 women with a CA125 level >=35 U/ml who were aged >=50 years and who did not have ovarian cancer, 20.

71 mong PLWH across all age groups except those aged >=75 years and was more common in women.

72 and a large proportion of prenatal patients aged <15 years) and target (more prenatal patients, loca

73 different between younger patients (n = 503 aged <=63 years) and older patients (n = 514 aged >=64 y

74 current seizures, is common in older adults (aged >65 years) and yet has received comparatively littl

75 phase 2 trial, we enrolled eligible adults (aged >=18 years) and children (aged between 2 and <18 ye

76 g of high prevalence groups (PWID and adults aged >=30 years) and rescreening (annually for PWID, oth

77 mpact in reducing hospitalizations in adults aged >=65 years, and VC improvements would have the larg

78 ing EPIONCHO-IBM exposure patterns, children aged <10 years are the most informative for seromonitori

79 Older adults (aged >=70 years) are at increased risk of severe disease

80 ute and chronic HCV infections among persons aged <=40 years as a proxy measure of IDU.

81 Patients with HF who were aged 75 years at hospital discharge.

82 Patients aged > 60 years at relapse had shorter second PFS (hazar

83 ith age stratification, women exposed to FHT aged >=45 years at the time of FHT prescription were mor

84 4/2015 influenza season from 232 individuals aged >=60 years at ILI-onset, followed by sampling 2-3 w

85 Adults aged >=18 years began D/C/F/TAF <=14 days from diagnosis

86 continuity was present in each of 6 patients aged <30 years but only 1 (2.7%) of 37 aged >=60 years.

87 l 3 VRQoL domains were evident only in those aged >=65 years compared with persons without incident V

88 e in these outcomes was heightened for those aged >=75 years compared with those aged <75 years.

89 associated ALRI hospitalizations in children aged <5 years, comparing those with underlying CHD to th

90 Pediatric cases were aged <18 years; congenital and perinatal infections were

91 Contacts without TB disease aged <5 years, contacts aged between 5 and 17 years with

92 hough incidence of IPD and PnCAP in children aged <5 years decreased by 38%, neither decreased in peo

93 rmed influenza for community-dwelling adults aged >65 years during the 2010-2011 to 2015-2016 influen

94 periods and tended to be greatest in adults aged >=65 years during combined RSV-flu outbreak periods

95 population of approximately 75 000 children aged <5 years, enabling incidence calculation.

96 Samples from children (aged <=13 years) enrolled during the 7 years of the pros

97 is was a cross-sectional study of MM in PLWH aged >=70 years from the Dat'AIDS French multicenter coh

98 ears, only 84.4% of approximately 10 000 HCP aged <40 years had protective antibody.

99 Men whose youngest child was aged >=20 years had higher risks of CD (OR = 1.22, 95% C

100 vel >=35 U/ml, 3.4% aged <50 years and 15.2% aged >=50 years had ovarian cancer.

101 Patients aged >=60 years had a significantly higher risk of death

102 s with the highest prevalence of young PWID (aged <=25 years) had low coverage of interventions to pr

103 Eligible patients (aged >=18 years) had deleterious germline BRCA1 or BRCA2

104 Eligible patients (aged >=18 years) had histologically confirmed CD20-posit

105 Among US-born adults aged >=20 years, HAV susceptibility prevalence was 74.1%

106 tions are driven mainly by older individuals aged >=65 years, highlighting the need for effective reg

107 mpared hospitalization costs for 2090 adults aged >= 60 years hospitalized with RSV or influenza by a

108 s predicted to occur among the US population aged >=65 years if vaccination were delayed until Octobe

109 lization due to enteric fever among children aged <5 years in Bangladesh.

110 within the AGS/AAPOS service areas, children aged <6 years in these potential service deserts were mo

111 Aboriginal community residents aged >2 years in seven remote communities were invited t

112 YPHIVs aged >=18 years in the Pediatric HIV/AIDS Cohort Study (

113 Data from 10,713 dentate participants aged >=30 years in NHANES 2009-2014 were used.

114 analyzed primary care records from patients aged >=65 years in England with community-onset UTI usin

115 ary 2001 through December 2015 among adults (aged >=18 years) in 15 clinical cohorts.

116 The analysis included 37,472 participants (aged >=19 years) in the Korea National Health and Nutrit

117 In patients with ACHD aged >=40 years, incident HFH was associated with high m

118 ncer among 25 871 US men aged >=50 and women aged >=55 years, including 5106 blacks.

119 levels through 1 year post-dose 2 in adults aged >=65 years irrespective of previous ZVL vaccination

120 rast, extending vaccination to women and men aged 45 years is predicted to reduce these outcomes by a

121 patitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin.

122 The study population was individuals aged >=15 years living in 14 urban and peri-urban "PopAR

123 treated with oseltamivir, most of whom were aged <5 years (n = 39).

124 1,768, aVE 23%, 95% CI 1%-40%) and patients aged >=65 years (n = 1,407, aVE 20%, 95% CI -5% to 40%),

125 20%, 95% CI -5% to 40%), but not in patients aged >=75 years (n = 905, aVE 5%, 95% CI -37% to 35%).

126 nalytical samples: n = 2740 for 1982 cohort, aged 30 years; n = 3592 for 1993 cohort, aged 18; n = 26

127 Eligible participants were adults (aged >=18 years) newly admitted to TFH facilities with a

128 and 550 comparable HIV-negative participants aged >= 45 years of the AGEhIV Cohort Study.

129 atients aged 0-17 years old and 154 patients aged 12 years old and above with food allergy were recru

130 The study included 5,899 participants aged 40+ years old.

131 and cohort studies of neonates and children aged <21 years old were eligible for inclusion when full

132 We included participants who were aged >18 years old, had a predialysis serum sodium >=135

133 , than immature juveniles, (iv) older males (aged >=4 years old) commenced spermatogenesis earlier th

134 s adopted with a total of 22,847 respondents aged >=60-years-old.

135 The 17 recommendations for individuals aged 12 years or older are reported in this Special Comm

136 Patients aged 12 years or older with HAE due to C1 inhibitor defi

137 dation applies to women and adolescent girls aged 13 years or older who are not currently diagnosed w

138 -randomised trial, we recruited participants aged 15 years or older from 15 outpatient departments at

139 People living with HIV aged 15 years or older who initiated ART at a programme

140 Individuals aged 15 years or older who were not previously identifie

141 ts were mothers or female primary caregivers aged 15 years or older with children aged 6-24 months at

142 Patients aged 15 years or older with resected stage IIIB-C or IV

143 GU (TR-DGU) in Germany between 2002 and 2015 aged 16 years or older and with an Injury Severity Score

144 r Trauma Network that included 1548 patients aged 16 years or older who underwent surgery for a lower

145 y, hospital course, and outcomes of patients aged 16 years or older with confirmed COVID-19 who had E

146 e epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, lo

147 andomised superiority trial included adults (aged 16 years or older) who presented to orthopaedic dep

148 Women aged 16 years or older, not already using hormonal contr

149 Patients who were aged 18 years or older (or aged 19 years or older in Sou

150 In both studies, eligible patients were aged 18 years or older and had an Eastern Cooperative On

151 Eligible patients were aged 18 years or older and had resectable American Joint

152 We recruited adults aged 18 years or older referred to Hospital da Restaurac

153 ed relationships, fathers or male caregivers aged 18 years or older were also eligible.

154 placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinum-sensitive, high-

155 Eligible patients were aged 18 years or older with a disabling ischaemic stroke

156 Eligible patients aged 18 years or older with active adult-onset psoriatic

157 Eligible patients were aged 18 years or older with an Eastern Cooperative Oncol

158 Patients aged 18 years or older with an Eastern Cooperative Oncol

159 The trial included women aged 18 years or older with an Eastern Cooperative Oncol

160 Patients with myelodysplastic syndromes were aged 18 years or older with an ECOG performance status s

161 survival outcomes were analysed in patients aged 18 years or older with biopsy-confirmed pancreatic

162 Women aged 18 years or older with completely excised non-low-r

163 icohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression followin

164 vanced, inoperable cervical cancer, who were aged 18 years or older with Eastern Cooperative Oncology

165 Eligible men were aged 18 years or older with female partners aged 18-45 y

166 rm, single centre, phase 2 trial in patients aged 18 years or older with HER2-positive metastatic oes

167 Eligible patients were aged 18 years or older with histologically or cytologica

168 , and Singapore) that enrolled men and women aged 18 years or older with histologically proven, unres

169 2018 (10 cycles), including 18 262 US adults aged 18 years or older with hypertension defined as syst

170 Eligible participants were women aged 18 years or older with International Federation of

171 hase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastat

172 DURANCE trial; E1A11), we recruited patients aged 18 years or older with newly diagnosed multiple mye

173 Patients aged 18 years or older with pathologically confirmed dif

174 Patients aged 18 years or older with previously untreated stage I

175 Men aged 18 years or older with progressing metastatic castr

176 Patients aged 18 years or older with relapsed or relapsed and ref

177 rse managers were excluded) and 829 patients aged 18 years or older, able to read and write Italian a

178 the biliary tract cancer cohort if they were aged 18 years or older, had BRAF(V600E)-mutated, unresec

179 nts were eligible for the study if they were aged 18 years or older, had cancers that were refractory

180 Eligible patients were aged 18 years or older, had stage IV or recurrent squamo

181 Eligible patients were aged 18 years or older, had untreated chronic lymphocyti

182 Eligible patients were aged 18 years or older, were hospitalised for acute hear

183 Eligible patients were women aged 18 years or older, who had hormone receptor-positiv

184 Most studies enrolled any adult aged 18 years or older.

185 6 months without virological failure and be aged 18 years or older.

186 e observational study, hospitalized patients aged 18 years or younger with stable kidney function and

187 Patients who were aged 18 years or older (or aged 19 years or older in South Korea) with germline BRC

188 nts were eligible for inclusion if they were aged 2 years or older, had been treated for a generalise

189 irst BI-RADS category 3 occurrence for women aged 25 years or older with no personal history of breas

190 We recruited non-pregnant women, aged 25 years or older, who were eligible for ablative t

191 partners younger than 30 years than in those aged 30 years or older (1.68, 1.35-2.09) and lower among

192 delines (from March 16, 2020) in individuals aged 30 years or older registered with a practice betwee

193 r dementia, analyzing data from participants aged 40 years or older in the National Health Insurance

194 Insured patients aged 40 years or older with newly diagnosed DM2 (n = 42

195 esion with depressive symptoms among persons aged 50 years or more in 16 different countries.

196 nk, we formed a cohort of 2,430,884 patients aged 50 years or older between 1995 and 2016.

197 ARTICIPANTS: There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and O

198 Subjects aged 50 years or older were identified from the Chinese

199 Adults aged 50 years or older with symptomatic knee osteoarthri

200 Patients were eligible if they were aged 50 years or older, had been taking acid-suppressant

201 e United States and comprising 32,531 adults aged 50 years or older.

202 the overall risk of depression among adults aged 50 years or older.

203 Patients aged 55 years or older had an absolute risk reduction of

204 t absolute effects were for men and patients aged 55 years or older.

205 Participants were community-dwelling adults aged 60 years or older from the National Study of Health

206 -point clinical trial including 160 patients aged 60 years or older with permanent atrial fibrillatio

207 Among adults aged 60 years or older with type 1 diabetes, continuous

208 icantly higher odds ratio (OR) for DM in men aged 64 years or younger (OR [95% confidence interval (C

209 E) and included non-institutionalized adults aged 65 years or older (mean age 74 years, 59% females)

210 ere 71 017 608 unique Medicare beneficiaries aged 65 years or older (mean age, 75.6 [SD, 9.2] years;

211 Individuals aged 65 years or older and without dementia at baseline

212 dy of Medicare fee-for-service beneficiaries aged 65 years or older between January 2004 and December

213 ion to 3.20 (95% BCrI 1.00-5.50) in patients aged 65 years or older who had more severe illness, como

214 ional study involving Medicare beneficiaries aged 65 years or older who underwent 1 of the following

215 cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischem

216 Among patients aged 65 years or older with acute ischemic stroke who we

217 ingdom and included 2600 randomized patients aged 65 years or older with vasodilatory hypotension (as

218 112 (42%) patients were aged 65 years or older, 181 (67%) had chemotherapy-refra

219 Among Medicare fee-for-service beneficiaries aged 65 years or older, dually enrolled beneficiaries ha

220 lts younger than 65 years, but not in adults aged 65 years or older.

221 those younger than 20 years to >66% of those aged 70 years or older).

222 13.7% were older than 70 years and 6.3% were aged 70 years or younger with at least one underlying co

223 3006 persons aged 75 years or older who were hospitalized with AMI an

224 in concentration on the survival of patients aged 80 years or older with NSTEMI.

225 o 304.9 deaths per 1000 cases among patients aged 85 years or older in the US.

226 All city residents aged six years or older were eligible and 9,899,828 (92.

227 increased among men whose youngest child was aged <=4 years (OR = 1.14, 95% CI: 1.02, 1.27).

228 A total of 340 adult (aged >=17 years) patients with confirmed encephalitis we

229 period 2007-2016, the proportion of patients aged >88 years, patients with BCVA <=0.1, and patients w

230 Among adults aged >=65 years, PCV13-type IPD decreased 68% (95% CI, -

231 3 to 2014 identified older adult inpatients, aged >=65 years, presenting for 8 common surgical condit

232 Adults aged >=65 years previously vaccinated with ZVL >=5 years

233 We analyzed Medicare beneficiaries aged >=65 years receiving intravenous thrombolytic treat

234 diabetes mellitus (T2DM) in younger people (aged <40 years), referred to as young-onset T2DM, has a

235 , non-interventional study enrolled patients aged >=18 years scheduled to receive DEX implant for DME

236 were pooled from 13 studies of 3,989 (94.1% aged <15 years) SM patients and 5,780 (79.6% aged <15 ye

237 ts (University of Michigan glaucoma patients aged >=40 years, taking >=1 glaucoma medication, who sel

238 dmission rate and hCFR were higher for those aged >=65 years than for those aged 50-64 years.

239 In patients in the HD13 trial who were aged <= 60 years, the 2-year, second PFS rate was 94.0%

240 etrospective study of 3120 diabetic patients aged >= 60 years, those taking metformin were less likel

241 Among Individuals aged >=50 years, treatment completion with 3HP-SAT was 8

242 aged <15 years) SM patients and 5,780 (79.6% aged <15 years) UM cases in Benin, Malaysia, Mozambique,

243 associations tended to be stronger in adults aged <65 years, unemployed, and those with lower levels

244 idence estimated from immunocompetent adults aged >=50 years unvaccinated with zoster vaccine live wh

245 x-case patient was highest among individuals aged >=65 years, versus the annual background incidence

246 rospective cohort study among 5,421 children aged 10 years, we measured general fat including body ma

247 Participants aged >= 60 years were recruited from 41 homes, and a com

248 All pregnant women aged >=15 years were followed-up during pregnancy and th

249 A total of 5011 patients aged >=65 years were admitted to Canadian Serious Outcom

250 ent interruption were evaluated and patients aged >=65 years were compared with selected younger pati

251 Patients aged >=65 years were less likely to complete TB treatmen

252 Those aged >=75 years were also more likely to have an adverse

253 Adults (aged >=18 years) were eligible for randomization on day

254 Individuals (aged >=2 years) were eligible to participate if they wer

255 of glaucoma or ocular hypertension who were aged >=40 years, were taking >=1 glaucoma medication, sp

256 d were infected with HIV; and 610 (61%) were aged >=5 years, were negative for HIV or had an unknown

257 were formed based on data from 1,212,295 men aged 18 years who were conscripted for military service

258 Subjects aged 66 years who underwent health examination from 2009

259 Adults aged >45 years who consumed foods with high antioxidant

260 We included 3,007,620 elderly individuals aged >= 65 years who had at least one routinely-prescrib

261 tion fraction <=35%) to a cohort of patients aged >=18 years who were evaluated in the ED at a Mayo C

262 StudyPopulation: Patients aged >=50 years who had undergone RD repair.

263 Medicare beneficiaries aged >=65 years who underwent endothelial keratoplasty (

264 System data for patients with incident ESKD aged >=66 years who started hemodialysis on a CVC in Jul

265 mean age = 51 years), including 14,956 women aged >=70 years who were free of both stroke and cogniti

266 Patients (aged >=16 years) who were being treated non-operatively

267 We prospectively recruited women (aged >=18 years) who attended these hospitals with suspe

268 We enrolled HIV-positive adults (aged >=18 years) who presented for their first routine H

269 Data for 11,753 individuals, aged >=30 years, who completed a periodontal examination

270 reating young adult and paediatric patients [aged <=21 years]), who received at least one dose of ent

271 Women aged 20 years with a history of chest radiotherapy.

272 Patients aged <18 years with confirmed CDI were randomized 2:1 to

273 MC, except for older adults with DM or those aged <65 years with CVA.

274 tacts were enrolled: 353 (44.1%) individuals aged <=17 years with a median age of 19 years (interquar

275 ncrease in systolic blood pressure among men aged <=67 years with diastolic blood pressure greater th

276 ysis), extremely old patients (such as those aged >80 years with multiple risk factors for bleeding),

277 rgia, based on the estimated 150 000 persons aged >=18 years with active HCV infection.

278 an immunocompromising condition, or contacts aged >=18 years with an immunocompromising condition wer

279 a from electronic health records of patients aged >=18 years with laboratory-confirmed COVID-19 admit

280 Eligible participants were WLHIV aged >=18 years with no history of anal HSIL.

281 After all ocular examinations adult's aged >=18 years with presenting Visual acuity of < 6/18

282 Adults aged >=65 years with pulmonary TB had less-advanced dise

283 The study enrolled older patients (aged >60 years) with newly diagnosed AML, not eligible f

284 We enrolled women (aged >= 18 years) with histologically confirmed stage II

285 mised phase 3 trial (JADE MONO-1), patients (aged >=12 years) with moderate-to-severe atopic dermatit

286 d from a prospective cohort study of adults (aged >=16 years) with CAP hospitalised at 2 university t

287 Adults (aged >=18 years) with a pathologically proven diagnosis

288 Eligible participants were adults (aged >=18 years) with active axial spondyloarthritis wit

289 Eligible patients were adults (aged >=18 years) with an Eastern Cooperative Oncology Gr

290 gible participants were HIV-positive adults (aged >=18 years) with CD4 counts of 150 cells per muL or

291 Participants were women (aged >=18 years) with histologically confirmed advanced

292 Adults (aged >=18 years) with histologically documented, localis

293 valuable population included adult patients (aged >=18 years) with locally advanced or metastatic ROS

294 phase 1b study, we enrolled adult patients (aged >=18 years) with locally advanced or metastatic, ME

295 Patients (aged >=18 years) with primary or recurrent biopsy-proven

296 We selected patients (aged >=18 years) with rectal cancer who had a clinical c

297 We enrolled adult patients (aged >=18 years) with relapsed or refractory large B-cel

298 study, we compared outcomes of 82 patients (aged >=18 years) with septic shock who received VA-ECMO

299 We included men and women (aged >=50 years) with either established or newly diagno

300 Eligible persons aged >=65 years (y) attending an influenza vaccination c